Answers are grounded in this paper and cite their sources.
Evidence from two randomized controlled studies suggests that functional and other outcomes are similar with use of recombinant human bone morphogenetic protein-2 (rhBMP-2) as with autograft in lumbar interbody fusion. At all postoperative intervals, the mean Oswestry back and leg pain scores improved in both treatment groups compared with preoperative score, but there were few statistically significant differences between treatment groups. Complications were reported as similar, other than the morbidity associated with donor site pain with iliac crest allograft. Overall results indicate that the use of rhBMP-2 may be an equivalent replacement for autograft in posterior lumbar interbody fusion, although the relative costs for these two approaches may be an important consideration.
No takes yet. Share an insight, caveat, or question.
A 2009 study studied this question.